Nordion Inc  

(Public, TSE:NDN)   Watch this stock  
Find more results for TSE:MDS
-0.10 (-0.75%)
Jul 9 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 13.30 - 13.40
52 week 7.42 - 14.27
Open 13.40
Vol / Avg. 4,240.00/62,174.00
Mkt cap 824.01M
P/E 2.77
Div/yield     -
EPS 4.80
Shares 61.91M
Beta 0.13
Inst. own     -
Sep 1, 2014
Q3 2014 Nordion Inc. Earnings Release (Estimated) Add to calendar
Jun 6, 2014
Extraordinary Shareholders Meeting
Jun 6, 2014
Annual Shareholders Meeting

Key stats and ratios

Q2 (Apr '14) 2013
Net profit margin 8.97% 101.87%
Operating margin 13.46% 94.80%
EBITD margin - 11.34%
Return on average assets 4.35% 45.36%
Return on average equity 5.70% 72.49%
Employees 411 -
CDP Score - -


447 March Rd.
+1-613-5922790 (Phone)
+1-613-5926937 (Fax)

Website links


Nordion Inc. (Nordion) is a global health science company, engaged providing products and services used for the prevention, diagnosis and treatment of disease. The Company�s business segments include Sterilization Technologies and Medical Isotopes as well as certain corporate functions and activities reported as Corporate and Other. On July 13, 2013, BTG Plc announced that it has completed the acquisition of Targeted Therapies division from Nordion Inc.

Officers and directors

Steven M. West President, Chief Executive Officer, Non-Independent Director
Age: 61
G. Peter Dans Chief Financial Officer
Grant Gardiner Senior Vice President, General Counsel, Corporate Secretary
Christopher Ashwood Senior Vice President - Corporate Services
Tamra Benjamin Vice President - Government and Public Affairs
Scott McIntosh Chief Operating Officer - Specialty Isotopes
William D. Anderson Non-Executive Independent Chairman of the Board
Age: 65
Jeffrey J. Brown Independent Director
Age: 52
William G. Dempsey Independent Director
Age: 62
Mary A. Mogford Independent Director
Age: 69